Omnicell, Inc., (NASDAQ:OMCL) announced today it has completed its acquisition of MTS Medication Technologies, Inc., which the company had previously stated on May 2nd, 2012 that it intended to do.
Randall Lipps, chairman, president and CEO of Omnicell had the following to say, “Providing medication management solutions across the entire spectrum of health care is aligned with the needs of our customers to increase efficiency by reducing recurrences of patient treatment needs. We believe that the addition of MTS to the existing Omnicell solutions uniquely positions Omnicell in the industry to supply the new demands for tracking and managing treatment beyond the acute care setting and use these capabilities to cut costs and improve outcomes.”
“Increasingly, health systems have strong financial and patient satisfaction incentives to actively work to reduce hospital readmissions, and medication adherence is a key component. With the addition of MTS, Omnicell is in a stronger-than-ever position to partner with healthcare organizations across the full continuum of patient care delivery,” added Mr. Lipps. “For example, Omnicell will now be able to address the costly, critical issue of non-adherence head-on, through medication packaging solutions and consumables that help patients and caregivers adhere to the prescribed medication regimen. We believe the new end-to-end Omnicell portfolio of innovations brings unmatched value to safe, effective medication management for healthcare organizations in both acute and non-acute care environments.”
Shares of OMCL closed down 1.94% to $14.19 per share at the end of trading today.